Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published:

  • Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

    Diabetes, Obesity and Metabolism Date published:

  • Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

    Unknown Date published:

  • Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure

    Clinical Journal of the American Society of Nephrology Date published:

  • Renal, Cardiovascular and Safety Outcomes of Canagliflozin in Patients with Type 2 Diabetes and Nephropathy in East and Southeast Asian Countries: Results from the CREDENCE Trial

    Journal of Diabetes Investigation Date published:

  • 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

    Diabetes Date published:

  • 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

    Diabetes Date published:

  • 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

    Diabetes Date published:

  • Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

    American Journal of Kidney Diseases Date published:

  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

    Stroke Date published:

  • Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Corrigendum

    ESC Heart Failure Date published:

  • The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

    Kidney International Date published:

  • Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

    Kidney International Reports Date published:

  • Cloth Masks May Prevent Transmission of COVID-19

    Annals of Internal Medicine Date published: